Quantcast

Latest Sipuleucel-T Stories

2011-02-24 05:00:00

SEATTLE, Feb. 24, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following conferences: Citi Global Health Care Conference, New York, NY on March 2, 2011 at 2:30 p.m. ET RBC Capital Markets' Healthcare Conference, New York, NY on March 3, 2011 at 11:30 a.m. ET Cowen Annual Healthcare Conference, Boston, MA on March 8, 2011 at 11:00 a.m. ET Roth Orange County Growth Stock Conference, Dana Point, CA on March 14, 2011 at 10:00...

2011-02-17 15:50:00

SEATTLE, Feb. 17, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following data presentations taking place at the 2011 Genitourinary Cancers Symposium annual meeting in Orlando, Florida. "Subsequent Treatment with APC8015F May Have Prolonged Survival of the Control Arm in Phase 3 Sipuleucel-T Studies," abstract #139. Reception and General Poster Session B: Prostate Cancer (A33) from 4:50 to 6:20 p.m. ET on Thursday, February 17, 2011. "Characterization of...

2011-02-08 10:47:00

MIAMI BEACH, Fla., Feb. 8, 2011 /PRNewswire-USNewswire/ -- The Mount Sinai Comprehensive Cancer Center in Miami Beach, Florida is one of only 50 sites throughout the country and, currently, the ONLY site in South Florida to treat advanced prostate cancer patients with a new cellular immunotherapy treatment called PROVENGE®, the first in a new therapeutic class known as autologous cellular immunotherapies. Provenge was recently approved by the U.S. Food and Drug...

2011-02-08 05:00:00

SEATTLE, Feb. 8, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will host a conference call on Tuesday, March 1, 2011 at 4:30 p.m. ET to review fourth quarter and year-end financial results. Access to the discussion may be obtained as follows: Time: 4:30 PM ET / 1:30 PM PT Date: March 1, 2011 1-877-548-9590 (domestic) or +1-720-545-0037 Dial-in: (international); conference pass code: 42044580...

2011-01-14 10:13:00

SEATTLE, Jan. 14, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the pricing of a public offering of $540 million aggregate principal amount of 2.875% convertible senior notes due January 15, 2016 (the "Notes") in an offering registered under the Securities Act of 1933, as amended (the "Securities Act"), which was upsized from its previously announced $500 million offering. The Notes will be convertible into cash, shares of Dendreon's common stock (the "Common...

2011-01-13 15:10:00

SEATTLE, Jan. 13, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of convertible senior notes due January 15, 2016 (the "Notes") in an offering registered under the Securities Act of 1933, as amended (the "Securities Act"). The Notes will be convertible into cash, shares of Dendreon's common stock (the "Common Stock") or a combination of cash and shares of...

2011-01-07 07:30:00

SEATTLE, Jan. 7, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced several updates regarding the U.S. commercialization of PROVENGE® (sipuleucel-T), the European strategy for PROVENGE, and progress on its pipeline. The Company will host a conference call at 9:00 a.m. ET to review additional details. "Last year was foundational for Dendreon with the successful introduction of PROVENGE as the world's first autologous cellular immunotherapy," said...

2011-01-06 15:00:00

SEATTLE, Jan. 6, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) management will host a conference call on Friday, January 7, 2011 at 9:00 a.m. ET to provide updates on U.S. commercialization progress, European strategy for PROVENGE, and pipeline progress. Date: Friday, January 7, 2011 Time: 9:00 a.m. ET / 6:00 a.m. PT Dial-in: 1-877-548-9590 (domestic) or +1-720-545-0037 (international); conference pass code 35063654 Webcast:...

2011-01-06 12:38:00

SAN FRANCISCO, Jan. 6, 2011 /PRNewswire/ -- Vista Partners announced today that it has updated coverage on Opexa Therapeutics, Inc. (Nasdaq: OPXA) and raised its twelve month target price from $4.40 to $6.50. Ross Silver, Principal Analyst at Vista Partners stated, "Opexa announced yesterday that their lead clinical candidate Tovaxin®, an autologous cellular immunotherapy for the treatment of Multiple sclerosis, is now positioned from a regulatory perspective to advance...

2011-01-05 06:30:00

SEATTLE, Jan. 5, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the 29th Annual J.P. Morgan Healthcare Conference in San Francisco on January 10, 2011 at 11:30 a.m. PT. The presentation will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com. If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'